NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $7.89 -0.10 (-1.25%) As of 02:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENZ Therapeutics Stock (NASDAQ:LENZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$7.92▼$8.4950-Day Range$6.65▼$11.7252-Week Range$6.61▼$50.40Volume425,214 shsAverage Volume980,221 shsMarket Capitalization$247.35 millionP/E RatioN/ADividend YieldN/APrice Target$29.80Consensus RatingModerate Buy Company Overview LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. Read More LENZ Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 633rd out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialLENZ Therapeutics has a consensus price target of $29.80, representing about 274.1% upside from its current price of $7.97.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.47) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted38.59% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 11.02, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 3.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.54 News SentimentLENZ Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows9 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.30% of the stock of LENZ Therapeutics is held by insiders.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Stock News HeadlinesLENZ Therapeutics to Participate in Upcoming Investor ConferencesMay 26 at 8:00 AM | globenewswire.comFDA approves VIZZ eye drops as alternative to reading glassesMay 26 at 7:48 AM | msn.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 29 at 1:00 AM | Brownstone Research (Ad)LENZ Therapeutics Inc.May 23, 2026 | marketwatch.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $29.80 Average Price Target from AnalystsMay 21, 2026 | americanbankingnews.comThings Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's DowngradeMay 16, 2026 | finance.yahoo.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their EstimatesMay 14, 2026 | finance.yahoo.comLENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...May 12, 2026 | finance.yahoo.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.00 at the beginning of 2026. Since then, LENZ shares have decreased by 50.2% and is now trading at $7.9660. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) posted its quarterly earnings data on Monday, May, 11th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.22. The firm had revenue of $1.90 million for the quarter, compared to analysts' expectations of $1.76 million. LENZ Therapeutics had a negative trailing twelve-month return on equity of 46.82% and a negative net margin of 519.30%. Read the conference call transcript. When did LENZ Therapeutics IPO? LENZ Therapeutics (LENZ) raised $224 million in an IPO on Thursday, June 24th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. Who are LENZ Therapeutics' major shareholders? Top institutional investors of LENZ Therapeutics include C WorldWide Group Holding A S (2.23%), Bank of America Corp DE (1.75%), Y Intercept Hong Kong Ltd (0.51%) and Affinity Asset Advisors LLC (0.32%). Insiders that own company stock include Ra Capital Management, LP, James W Mccollum, Daniel R Chevallard and Shawn Olsson. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/11/2026Today5/29/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LENZ's financial health is in the Red zone, according to TradeSmith. LENZ has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees110Year Founded2013Price Target and Rating Average Price Target for LENZ Therapeutics$29.80 High Price Target$50.00 Low Price Target$12.00 Potential Upside/Downside+274.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.13 million Net Margins-519.30% Pretax Margin-516.91% Return on Equity-46.82% Return on Assets-43.32% Debt Debt-to-Equity RatioN/A Current Ratio10.40 Quick Ratio10.26 Sales & Book Value Annual Sales$19.09 million Price / Sales13.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.86 per share Price / Book1.01Miscellaneous Outstanding Shares31,350,000Free Float28,752,000Market Cap$249.73 million OptionableN/A Beta0.62 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:LENZ) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
